Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GO Therapeutics has signed a license agreement with Roche for new glycotargeting bispecific cancer treatment.
Image: Roche's location in Basel. Photo: courtesy of F. Hoffmann-La Roche Ltd.
Subscribe to our email newsletter
As per terms of the deal, Roche will secure worldwide and exclusive license from GO Therapeutics for cancer-specific targeting antibodies.
The license will allow Roche to develop and commercialize new glycotargeting bispecific antibody.
Under the deal, GO Therapeutics will secure upfront and near-term milestones of $9m from Roche.
GO Therapeutics will also be eligible to secure up to $186m in potential milestone payments and mid-single-digit to low double-digit royalties on any future product sales.
Based in Cambridge of Massachusetts, GO Therapeutics is involved in applying new advances in glycoproteomics for the development of antibody-based cancer therapeutics.
The firm’s cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to restrict cancer.
GO Therapeutics’ platform and technologies are used in the development of antibody-drug-conjugates, bispecific T-cell engagers and immune-based cell therapies.
The company is currently involved in the development of a novel class of tumor-specific glycoprotein antigens, which are not found on healthy cells.
These antibodies are said to be suitable targets for bi-specific antibody T-cell engagement, CAR-T and ADC therapies.
In addition, GO’s lead antibody development program is based on a bispecific antibody for T cell-redirection therapy.
The company noted that it has advanced tools and techniques to identify sites of O-linked glycosylation on a wide range of proteins targets.
It will apply O-glycans at the plasma membrane to develop novel hybrid epitopes, which are part protein and O-glycan structure.
GO Therapeutics CEO Constantine Theodoropulos said: “We are excited about this collaboration to develop an innovative immune-redirected therapy to potentially improve the lives of patients suffering from cancer in the future.”
“GO’s glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates).
“Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies.”
